Prosthetic Joint Infections Missed in Patients with Rheumatic Diseases
Standard diagnostic methods are not adequate to identify prosthetic joint infections (PJIs) in patients with rheumatic diseases, according to findings from a new study by researchers from Hospital for Special Surgery (HSS) in New York City. The study was presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting in Atlanta on November 12.
Lead study author Susan M. Goodman, MD, a rheumatologist at HSS, said that while patients with rheumatic diseases are more prone to developing PJIs, it is also harder to make a PJI diagnosis in this population because many of the typical inflammation features of PJIs are similar to those seen in inflammatory arthritis flares. “If a patient with osteoarthritis comes in with a swollen and inflamed prosthetic joint, it is an infection until proven otherwise, but for patients with rheumatoid arthritis, it can be very hard to sort out whether this is part of an overall flare of disease or if it is a true infection,” she said. “None of the available tests are that helpful.”
The researchers launched the new study to examine the clinical and microbiological features of total hip and total knee arthroplasty PJIs in patients with rheumatic diseases and osteoarthritis. The researchers used the HSS institutional PJI registry to create a retrospective cohort of total hip/total knee replacement PJIs from 2009 to 2016. They identified 807 PJI cases, including 36 in patients with rheumatic disease and 771 in patients with osteoarthritis. Culture-negative cases were defined as PJIs with no evidence of microbial growth in intraoperative cultures; culture-positive PJIs were defined by positive microbial growth.
Among the findings, the researchers discovered that patients with rheumatic diseases had a higher proportion of culture-negative PJIs (27% vs 14%; P=0.02). “Patients with rheumatic diseases who were culture negative were less likely to meet the pathology criteria for infections than the ones who were culture positive, and they did a little worse,” said Dr. Goodman. One-year survivorship of culture-negative osteoarthritis and culture-negative rheumatic disease were 87% and 66%, respectively, and 47% for culture-positive rheumatic disease.
“The main message is that patients with rheumatic disease seem to have more culture-negative prosthetic joint infections than patients with osteoarthritis, but what we don’t know is what that means in terms of long-term management,” said Dr. Goodman. “We had the feeling that we were missing something with our rheumatic disease patients who were coming in with prosthetic joint infections, so I wasn’t surprised by our findings, but it pointed out how much more we need to do to really understand this.”
Dr. Goodman said the next step is to do a prospective study in patients with rheumatic disease, which will provide the standard diagnostic tests for PJIs but also use Next Generation Sequencing including cell-free DNA methods to better identify bacteria present in tissue.
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 14th consecutive year), No. 2 in rheumatology by U.S. News & World Report (2023-2024), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2023-2024). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a fourth consecutive year (2023). Founded in 1863, the Hospital has the lowest readmission rates in the nation for orthopedics, and among the lowest infection and complication rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. In addition, more than 200 HSS clinical investigators are working to improve patient outcomes through better ways to prevent, diagnose, and treat orthopedic, rheumatic and musculoskeletal diseases. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 165 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.